Yes, when administered by trained professionals using medical-grade compounds
It promotes lipolysis through growth hormone receptor pathways, which differs from the NNMT inhibition mechanism of 5-amino-1mq
Additional caution or monitoring may be appropriate in research settings involving: Pregnancy- or lactation-related research models, where limited safety data is available Active cancer-, tumor-, or abnormal proliferative research models, where NAD-related and metabolic-signaling pathways may influence cellular-signaling mechanisms Cardiovascular- or uncontrolled-hypertension research models, where metabolic-pathway modulation may influence cardiovascular-related biomarkers in some experimental settings Thyroid-related or endocrine research models, where metabolic-pathway investigations may influence endocrine-related observations Diabetes- or glucose-regulation research models, where insulin- and glucose-related pathways may warrant closer monitoring in experimental settings Moderate to severe hepatic- or renal-impairment research models, where compound metabolism or clearance mechanisms may be altered Autoimmune- or inflammatory-response research models, where immune-metabolic signaling pathways may influence inflammatory-related biomarkers or cytokine observations Research conditions, dosage ranges, administration frequency, protocol duration, and concurrent compounds may influence tolerability observations across experimental settings
Preclinical studies report approximately 1.6 increases in intracellular NAD+ following NNMT inhibition in adipocyte models
